Hengrui Yiyao Unit Cleared to Begin SHR-3201 Clinical Trial
2026-10-15 · 3 min read · AlphaGBM
At a glance
Hengrui Yiyao said its subsidiary, Beijing Shengdi Yiyao, received a clinical-trial approval notice from China’s drug regulator for SHR-3201 injection and plans to begin a trial soon. The company described the internally developed drug as a potential treatment for Alzheimer’s disease that may clear disease biomarkers in patients’ brains and slow cognitive decline.
Summary
Hengrui Yiyao said its subsidiary, Beijing Shengdi Yiyao, received a clinical-trial approval notice from China’s drug regulator for SHR-3201 injection and plans to begin a trial soon. The company described the internally developed drug as a potential treatment for Alzheimer’s disease that may clear disease biomarkers in patients’ brains and slow cognitive decline.